Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.
van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT.
van Stolk R, et al. Among authors: elson p.
Clin Cancer Res. 2000 Jan;6(1):78-89.
Clin Cancer Res. 2000.
PMID: 10656435
Clinical Trial.